Grifols (NASDAQ:GRFS) Stock Jumps 7.2% – What’s Next?

Shares of Grifols, S.A. (NASDAQ:GRFS) shot up 7.2% during trading on Monday. The stock traded as high as $8.01 and last traded at $8.1050. Approximately 192,511 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 636,375 shares. The stock had previously closed at $7.56.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GRFS. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. cut their target price on Grifols from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Monday. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Finally, Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Grifols presently has an average rating of “Reduce” and a consensus price target of $9.00.

Grifols Stock Up 1.2%

The company has a market cap of $5.58 billion, a P/E ratio of 43.02, a PEG ratio of 0.28 and a beta of 0.70. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The firm has a fifty day moving average price of $7.59 and a 200 day moving average price of $8.03.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Flat Footed LLC raised its stake in shares of Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock worth $11,007,000 after buying an additional 287,867 shares during the last quarter. Tidal Investments LLC boosted its holdings in Grifols by 9.8% during the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after buying an additional 109,612 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Grifols by 15.4% in the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock valued at $6,301,000 after acquiring an additional 104,850 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of Grifols by 13.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock valued at $4,193,000 after acquiring an additional 72,037 shares during the last quarter. Finally, Quantinno Capital Management LP raised its position in shares of Grifols by 42.0% in the 1st quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company’s stock valued at $2,829,000 after acquiring an additional 104,418 shares during the period.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.